Australian medical cannabis company Little Green Pharma (ASX: LGP) has reached a major offtake agreement with Demecan to distribute cannabis products across Germany. With the German medical cannabis market estimated to be worth €7.7bn (A$11.2bn) by 2028, this opportunity marks a massive milestone for the Company. In July 2021, LGP acquired a world-class cultivation site
Read More
There is an increasingly growing body of research globally into the use of psychedelic medicines to treat various health conditions. To date, this research has produced highly encouraging results and has promoted the development of an extensive psychedelic industry, which has kicked off in North America and the United Kingdom. The industry has now made
Read More
Advancing their research and development for medicinal cannabis applications, Little Green Pharma (ASX: LGP) has joined the global movement for use of psychedelics for treatment of mental illness having secured regulatory approval to supply psilocybin. The approvals come in the form of a Schedule 9 licence granted by the WA Department of Health which enables
Read More
Members of private health insurer Health Insurance Fund (HIF) will be given priority access to Little Green Pharma (ASX: LGP) and their research into medicinal cannabis with the two commencing a strategic partnership focused on improving patient quality of life. Under the partnership, HIF members will be given priority participation in Little Green Pharma product
Read More
Australian cannabis company Little Green Pharma (ASX: LGP) has reached a major commercial achievement in their long-term strategy having been granted a manufacturing licence for cannabis products at their newly commissioned facility in Western Australia. “The grant represents the culmination of LGP’s long-term regulatory strategy and is a clear watershed moment for the Company. The
Read More
Having been subject to a harsh reality check over the last year or so, the ASX listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the ailing masses. But the path to the pharmacy is likely to be harder than
Read More